NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today ...

Calidi Biotherapeutics stock was up 171.84% in pre-market trading on Wednesday, following a 39.47% rally yesterday. However, ...

Calidi Biotherapeutics Inc. CLDI stock surged by 39.47% in the after-hours trading session on Tuesday. The stock price ...

Ladenburg Thalmann & Co, Inc. is acting as the exclusive placement agent for the offering.

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today ...

Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotech firm developing targeted therapies for genetic medicine delivery, announced a ...

Calidi Biotherapeutics Inc. has spent over 10 years developing a groundbreaking platform for the systemic delivery of genetic medicines that can precisely target tumors. One of the company's core ...

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ('Calidi” or the 'Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of ...

Calidi Biotherapeutics announced a public offering of 5 million shares at $0.85 each, aiming for $4.25 million in proceeds. Quiver AI Summary Calidi Biotherapeutics, Inc. announced the pricing of ...

Calidi Biotherapeutics secures $4.6 million through warrant exerciseCalidi Biotherapeutics is developing targeted therapies designed to deliver genetic medicines to disease sites. The company’s ...

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease.